Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity
ABSTRACTPurpose:To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).Methods:Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Gro...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Conselho Brasileiro de Oftalmologia
2015-10-01
|
Series: | Arquivos Brasileiros de Oftalmologia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000550079&lng=en&tlng=en |
id |
doaj-ce7f1de541954570ba19c4d5d71e6110 |
---|---|
record_format |
Article |
spelling |
doaj-ce7f1de541954570ba19c4d5d71e61102020-11-24T23:44:05ZengConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia1678-29252015-10-0178530030410.5935/0004-2749.20150079S0004-27492015000550079Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurityMurat GunayGokhan CelikBetul Onal GunayAlev AktasGuner KaratekinFahri OvaliABSTRACTPurpose:To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).Methods:Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations.Results:Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively).Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000550079&lng=en&tlng=enBevacizumabInjeções intravítreaTerapia a laserRetinopatia da prematuridadeResultado do tratamento |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Murat Gunay Gokhan Celik Betul Onal Gunay Alev Aktas Guner Karatekin Fahri Ovali |
spellingShingle |
Murat Gunay Gokhan Celik Betul Onal Gunay Alev Aktas Guner Karatekin Fahri Ovali Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity Arquivos Brasileiros de Oftalmologia Bevacizumab Injeções intravítrea Terapia a laser Retinopatia da prematuridade Resultado do tratamento |
author_facet |
Murat Gunay Gokhan Celik Betul Onal Gunay Alev Aktas Guner Karatekin Fahri Ovali |
author_sort |
Murat Gunay |
title |
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity |
title_short |
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity |
title_full |
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity |
title_fullStr |
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity |
title_full_unstemmed |
Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity |
title_sort |
evaluation of 2-year outcomes following intravitreal bevacizumab (ivb) for aggressive posterior retinopathy of prematurity |
publisher |
Conselho Brasileiro de Oftalmologia |
series |
Arquivos Brasileiros de Oftalmologia |
issn |
1678-2925 |
publishDate |
2015-10-01 |
description |
ABSTRACTPurpose:To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).Methods:Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations.Results:Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively).Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies. |
topic |
Bevacizumab Injeções intravítrea Terapia a laser Retinopatia da prematuridade Resultado do tratamento |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492015000550079&lng=en&tlng=en |
work_keys_str_mv |
AT muratgunay evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity AT gokhancelik evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity AT betulonalgunay evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity AT alevaktas evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity AT gunerkaratekin evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity AT fahriovali evaluationof2yearoutcomesfollowingintravitrealbevacizumabivbforaggressiveposteriorretinopathyofprematurity |
_version_ |
1725500123311505408 |